What is Bio-Thera Solutions?
Bio-Thera Solutions, also known as Biotech Therapeutics Co., Ltd., is a global biopharmaceutical enterprise headquartered in Guangzhou, China. The company is dedicated to pioneering next-generation antibody therapeutics for critical conditions including cancer, autoimmune disorders, and cardiovascular diseases. Its portfolio includes marketed products, such as the first domestically produced adalimumab injection, developed under stringent GMP-compliant quality systems across the US, EU, and China. Bio-Thera Solutions is committed to addressing unmet clinical needs through innovation and strategic collaborations, aiming to broaden its market reach, particularly in Southeast Asia. The company is publicly listed on the Shanghai Stock Exchange (688177).
How much funding has Bio-Thera Solutions raised?
Bio-Thera Solutions has raised a total of $241M across 1 funding round:
Stock Offering
$241M
Stock Issuance/Offering (2020): $241M, investors not publicly disclosed
What's next for Bio-Thera Solutions?
The substantial enterprise-level funding Bio-Thera Solutions has attracted signals a pivotal growth phase, likely focused on scaling its development pipeline and expanding market penetration. This strategic investment will undoubtedly fuel further research and development into novel antibody drugs, reinforcing its position in the competitive biopharmaceutical landscape. The company's emphasis on addressing urgent clinical needs suggests a continued trajectory towards bringing innovative treatments to patients globally.
See full Bio-Thera Solutions company page
